• SPX
  • $5,952.75
  • 0.07 %
  • $4.04
  • DJI
  • $44,125.80
  • 0.58 %
  • $255.44
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,266.48
  • 1.44 %
  • $117.21
  • IXIC
  • $18,927.17
  • -0.24 %
  • -$45.25
Salarius Pharmaceuticals, Inc. (SLRX) Stock Price, News & Analysis

Salarius Pharmaceuticals, Inc. (SLRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.37

-$0.09

(-6.08%)

Day's range
$1.37
Day's range
$1.44
50-day range
$1.26
Day's range
$2.35
  • Country: US
  • ISIN: US79400X3052
52 wk range
$1.26
Day's range
$7.27
  • CEO: Mr. David J. Arthur M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -31.26
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (SLRX)
  • Company Salarius Pharmaceuticals, Inc.
  • Price $1.37
  • Changes Percentage (-6.08%)
  • Change -$0.09
  • Day Low $1.37
  • Day High $1.44
  • Year High $7.27

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/20/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.02
  • Trailing P/E Ratio -0.2
  • Forward P/E Ratio -0.2
  • P/E Growth -0.2
  • Net Income $-12,543

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Salarius Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of SLRX in the last quarter?

    In the last quarter Salarius Pharmaceuticals, Inc. earnings were on Friday, August, 9th. The Salarius Pharmaceuticals, Inc. maker reported -$2.37 EPS for the quarter, beating analysts' consensus estimates of -$53.60 by $51.23.

  • What is the Salarius Pharmaceuticals, Inc. stock price today?

    Today's price of Salarius Pharmaceuticals, Inc. is $1.37 — it has decreased by -6.08% in the past 24 hours. Watch Salarius Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Salarius Pharmaceuticals, Inc. release reports?

    Yes, you can track Salarius Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Salarius Pharmaceuticals, Inc. stock forecast?

    Watch the Salarius Pharmaceuticals, Inc. chart and read a more detailed Salarius Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Salarius Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Salarius Pharmaceuticals, Inc. stock ticker.

  • How to buy Salarius Pharmaceuticals, Inc. stocks?

    Like other stocks, SLRX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Salarius Pharmaceuticals, Inc.'s EBITDA?

    Salarius Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Salarius Pharmaceuticals, Inc.’s financial statements.

  • What is the Salarius Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Salarius Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Salarius Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Salarius Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Salarius Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Salarius Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.